View Item 

Show simple item record

Monoclonal antibodies in the treatment of multiple myeloma
dc.contributor.authorRichardson, Paul G.en_US
dc.contributor.authorLonial, Sagaren_US
dc.contributor.authorJakubowiak, Andrzej J.en_US
dc.contributor.authorHarousseau, Jean‐lucen_US
dc.contributor.authorAnderson, Kenneth C.en_US
dc.date.accessioned2011-11-10T15:32:50Z
dc.date.available2012-11-02T18:56:39Zen_US
dc.date.issued2011-09en_US
dc.identifier.citationRichardson, Paul G.; Lonial, Sagar; Jakubowiak, Andrzej J.; Harousseau, Jean‐luc ; Anderson, Kenneth C. (2011). "Monoclonal antibodies in the treatment of multiple myeloma." British Journal of Haematology 154(6). <http://hdl.handle.net/2027.42/86883>en_US
dc.identifier.issn0007-1048en_US
dc.identifier.issn1365-2141en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/86883
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherMultiple Myelomaen_US
dc.subject.otherMonoclonal Antibodiesen_US
dc.subject.otherNovel Therapiesen_US
dc.subject.otherNovel Targetsen_US
dc.subject.otherTargeted Therapiesen_US
dc.titleMonoclonal antibodies in the treatment of multiple myelomaen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDana‐Farber Cancer Institute, Boston, MA, USAen_US
dc.contributor.affiliationotherDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USAen_US
dc.contributor.affiliationotherCentre Rene Gauducheau, Nantes, Franceen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/86883/1/j.1365-2141.2011.08790.x.pdf
dc.identifier.doi10.1111/j.1365-2141.2011.08790.xen_US
dc.identifier.sourceBritish Journal of Haematologyen_US
dc.identifier.citedreferenceAgura, E., Niesvizky, R., Matous, J., Munshi, N., Hussein, M., Parameswaran, R.V., Tarantolo, S., Whiting, N.C., Drachman, J.G. & Zonder, J.A. ( 2009 ) Dacetuzumab (SGN‐40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a phase 1b study. Blood (ASH Annual Meeting Abstracts), 114, Abstract 2870.en_US
dc.identifier.citedreferenceBurton, J.D., Ely, S., Reddy, P.K., Stein, R., Gold, D.V., Cardillo, T.M. & Goldenberg, D.M. ( 2004 ) CD74 is expressed by multiple myeloma and is a promising target for therapy. Clinical Cancer Research, 10, 6606 – 6611.en_US
dc.identifier.citedreferenceCallander, N.S., Markovina, S., Juckett, M.B., Wagner, E., Kolesar, J., Longo, W., Williams, E.C., Kim, K., Werndli, J. & Miyamoto, S. ( 2009 ) The addition of bevacizumab (B) to lenalidomide and low dose dexamethasone does not significantly increase response in relapsed or refractory multiple myeloma (NCI#7317). Blood (ASH Annual Meeting Abstracts), 114, Abstract 3885.en_US
dc.identifier.citedreferenceCampbell, K.S. & Purdy, A.K. ( 2011 ) Structure/function of human killer cell immunoglobulin‐like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology, 132, 315 – 325.en_US
dc.identifier.citedreferenceDi Bernardo, A., Macor, P., Guarnotta, C., Franco, G., Florena, A.M., Tedesco, F. & Tripodo, C. ( 2010 ) Humoral immunotherapy of multiple myeloma: perspectives and perplexities. Expert Opinion on Biological Therapy, 10, 863 – 873.en_US
dc.identifier.citedreferenceFulciniti, M., Hideshima, T., Vermot‐Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z., Patel, N., Smith, E.S., Wang, W., Prabhala, R., Tai, Y.T., Tassone, P., Anderson, K.C. & Munshi, N.C. ( 2009a ) A high‐affinity fully human anti‐IL‐6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research, 15, 7144 – 7152.en_US
dc.identifier.citedreferenceFulciniti, M., Tassone, P., Hideshima, T., Vallet, S., Nanjappa, P., Ettenberg, S.A., Shen, Z., Patel, N., Tai, Y.T., Chauhan, D., Mitsiades, C., Prabhala, R., Raje, N., Anderson, K.C., Stover, D.R. & Munshi, N.C. ( 2009b ) Anti‐DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 114, 371 – 379.en_US
dc.identifier.citedreferenceHayashi, T., Treon, S.P., Hideshima, T., Tai, Y.T., Akiyama, M., Richardson, P., Chauhan, D., Grewal, I.S. & Anderson, K.C. ( 2003 ) Recombinant humanized anti‐CD40 monoclonal antibody triggers autologous antibody‐dependent cell‐mediated cytotoxicity against multiple myeloma cells. British Journal of Haematology, 121, 592 – 596.en_US
dc.identifier.citedreferenceHeath, D.J., Chantry, A.D., Buckle, C.H., Coulton, L., Shaughnessy, Jr, J.D., Evans, H.R., Snowden, J.A., Stover, D.R., Vanderkerken, K. & Croucher, P.I. ( 2009 ) Inhibiting Dickkopf‐1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. Journal of Bone and Mineral Research, 24, 425 – 436.en_US
dc.identifier.citedreferenceHsi, E.D., Steinle, R., Balasa, B., Szmania, S., Draksharapu, A., Shum, B.P., Huseni, M., Powers, D., Nanisetti, A., Zhang, Y., Rice, A.G., van Abbema, A., Wong, M., Liu, G., Zhan, F., Dillon, M., Chen, S., Rhodes, S., Fuh, F., Tsurushita, N., Kumar, S., Vexler, V., Shaughnessy, Jr, J.D., Barlogie, B., van Rhee, F., Hussein, M., Afar, D.E.H. & Williams, M.B. ( 2008 ) CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clinical Cancer Research, 14, 2775 – 2784.en_US
dc.identifier.citedreferenceIkeda, H., Hideshima, T., Fulciniti, M., Lutz, R.J., Yasui, H., Okawa, Y., Kiziltepe, T., Vallet, S., Pozzi, S., Santo, L., Perrone, G., Tai, Y.T., Cirstea, D., Raje, N.S., Uherek, C., Dalken, B., Aigner, S., Osterroth, F., Munshi, N., Richardson, P. & Anderson, K.C. ( 2009 ) The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138‐positive multiple myeloma cells in vitro and in vivo. Clinical Cancer Research, 15, 4028 – 4037.en_US
dc.identifier.citedreferenceIshii, T., Chanan‐Khan, A., Jafferjee, J., Ersing, N., Takahashi, H., Mizutani, M., Shiotsu, Y. & Hanai, N. ( 2008 ) A humanized anti‐ganglioside GM2 antibody, BIW‐8962, exhibits ADCC/CDC activity against multiple myeloma cells and potent anti‐tumor activity in mouse xenograft models. Blood (ASH Annual Meeting Abstracts), 112, Abstract 1718.en_US
dc.identifier.citedreferenceJagannath, S., Kyle, R.A., Palumbo, A., Siegel, D.S., Cunningham, S. & Berenson, J. ( 2010 ) The current status and future of multiple myeloma in the clinic. Clinical Lymphoma, Myeloma and Leukemia, 10, 28 – 43.en_US
dc.identifier.citedreferenceJakubowiak, A.J., Benson, Jr, D.M., Bensinger, W., Siegel, D.S., Zimmerman, T., Mohrbacher, A., Richardson, P., Afar, D.E.H., Singhal, A.K. & Anderson, K.C. ( 2010 ) Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: updated results of a phase 1 study. Blood (ASH Annual Meeting Abstracts), 116, Abstract 3023.en_US
dc.identifier.citedreferenceJemal, A., Siegel, R., Xu, J. & Ward, E. ( 2010 ) Cancer statistics, 2010. CA: A Cancer Journal for Clinicians, 60, 277 – 300.en_US
dc.identifier.citedreferenceKapoor, P., Greipp, P.T., Morice, W.G., Rajkumar, S.V., Witzig, T.E. & Greipp, P.R. ( 2008 ) Anti‐CD20 monoclonal antibody therapy in multiple myeloma. British Journal of Haematology, 141, 135 – 148.en_US
dc.identifier.citedreferenceKastritis, E., Charidimou, A., Varkaris, A. & Dimopoulos, M.A. ( 2009 ) Targeted therapies in multiple myeloma. Targeted Oncology, 4, 23 – 36.en_US
dc.identifier.citedreferenceKristinsson, S.Y., Landgren, O., Dickman, P.W., Derolf, A.R. & Bjorkholm, M. ( 2007 ) Patterns of survival in multiple myeloma: a population‐based study of patients diagnosed in Sweden from 1973 to 2003. Journal of Clinical Oncology, 25, 1993 – 1999.en_US
dc.identifier.citedreferenceKumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Zeldenrust, S.R., Dingli, D., Russell, S.J., Lust, J.A., Greipp, P.R., Kyle, R.A. & Gertz, M.A. ( 2008 ) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516 – 2520.en_US
dc.identifier.citedreferenceLonial, S., Vij, R., Harousseau, J.‐L., Facon, T., Moreau, P., Leleu, X., Mazumder, A., Kaufman, J.L., Westland, C.E., Tsao, C., Singhal, A.K. & Jagannath, S. ( 2010 ) Elotuzumab in combination with lenalidomide and low‐dose dexamethasone in patients with relasped/refractory multiple myeloma: results of a phase 1 study. Blood (ASH Annual Meeting Abstracts), 116, Abstract 1936.en_US
dc.identifier.citedreferenceLutz, R.J. & Whiteman, K.R. ( 2009 ) Antibody‐maytansinoid conjugates for the treatment of myeloma. Monoclonal Antibodies, 1, 548 – 551.en_US
dc.identifier.citedreferenceMechtersheimer, G., Staudter, M. & Möller, P. ( 1992 ) Expression of the natural killer (NK) cell‐associated antigen CD56 (Leu‐19), which is identical to the 140‐kDa isoform of N‐CAM, in neural and skeletal muscle cells and tumors derived therefrom. Annals of the New York Academy of Sciences, 650, 311 – 316.en_US
dc.identifier.citedreferenceMhaskar, R., Redzepovic, J., Wheatley, K., Clark, O.A., Miladinovic, B., Glasmacher, A., Kumar, A. & Djulbegovic, B. ( 2010 ) Bisphosphonates in multiple myeloma. The Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD003188.en_US
dc.identifier.citedreferenceMoreau, P., Harousseau, J.‐L., Wijdenes, J., Morineau, N., Milpied, N. & Bataille, R. ( 2000 ) A combination of anti‐interleukin 6 murine monoclonal antibody with dexamethasone and high‐dose melphalan induces high complete response rates in advanced multiple myeloma. British Journal of Haematology, 109, 661 – 664.en_US
dc.identifier.citedreferenceMoreau, P., Hullin, C., Garban, F., Yakoub‐Agha, I., Benboubker, L., Attal, M., Marit, G., Fuzibet, J.‐G., Doyen, C., Voillat, L., Berthou, C., Ketterer, N., Casassus, P., Monconduit, M., Michallet, M., Najman, A., Sotto, J.‐J., Bataille, R., Harousseau, J.‐L. & for the Intergroupe Francophone du Myelome group ( 2006 ) Tandem autologous stem cell transplantation in high‐risk de novo multiple myeloma: final results of the prospective and randomized IFM 99‐04 protocol. Blood, 107, 397 – 403.en_US
dc.identifier.citedreferenceMoreaux, J., Hose, D., Reme, T., Jourdan, E., Hundemer, M., Legouffe, E., Moine, P., Bourin, P., Moos, M., Corre, J., Mohler, T., De Vos, J., Rossi, J.F., Goldschmidt, H. & Klein, B. ( 2006 ) CD200 is a new prognostic factor in multiple myeloma. Blood, 108, 4194 – 4197.en_US
dc.identifier.citedreferenceNiesvizky, R., Ely, S., Mark, T., Aggarwal, S., Gabrilove, J.L., Wright, J.J., Chen‐Kiang, S. & Sparano, J.A. ( 2011 ) Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer, 117, 336 – 342.en_US
dc.identifier.citedreferenceRaschko, M., Markovina, S., Miyamoto, S., Longo, W., Williams, E., McFarland, T., Werndli, J., Wagner, E., Juckett, M. & Callander, N. ( 2007 ) Phase II trial of bevacizumab combined with low dose dexamethasone and lenalidomide (BEV/REV/DEX) for relapsed or refractory myeloma (MM). Blood (ASH Annual Meeting Abstracts), 110, Abstract 1173.en_US
dc.identifier.citedreferencevan Rhee, F., Szmania, S.M., Dillon, M., van Abbema, A.M., Li, X., Stone, M.K., Garg, T.K., Shi, J., Moreno‐Bost, A.M., Yun, R., Balasa, B., Ganguly, B., Chao, D., Rice, A.G., Zhan, F., Shaughnessy, Jr, J.D., Barlogie, B., Yaccoby, S. & Afar, D.E.H. ( 2009 ) Combinatorial efficacy of anti‐CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Molecular Cancer Therapeutics, 8, 2616 – 2624.en_US
dc.identifier.citedreferencevan Rhee, F., Fayad, L., Voorhees, P., Furman, R., Lonial, S., Borghaei, H., Sokol, L., Crawford, J., Cornfeld, M., Qi, M., Qin, X., Herring, J., Casper, C. & Kurzrock, R. ( 2010 ) Siltuximab, a novel anti‐interleukin‐6 monoclonal antibody, for Castleman’s disease. Journal of Clinical Oncology, 28, 3701 – 3708.en_US
dc.identifier.citedreferenceRichardson, P.G., Mitsiades, C., Schlossman, R., Munshi, N. & Anderson, K. ( 2007 ) New drugs for myeloma. Oncologist, 12, 664 – 689.en_US
dc.identifier.citedreferenceRichardson, P.G., Moreau, P., Jakubowiak, A.J., Facon, T., Jagannath, S., Vij, R., Reece, D.E., White, D.J., Raab, M.S., Benboubker, L., Rossi, J.‐F., Tsao, C., Fry, J., Berman, D., Singhal, A.K. & Lonial, S. ( 2010 ) Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: interim results of a phase 2 study. Blood (ASH Annual Meeting Abstracts), 116, Abstract 986.en_US
dc.identifier.citedreferenceRobillard, N., Avet‐Loiseau, H., Garand, R., Moreau, P., Pineau, D., Rapp, M.‐J., Harousseau, J.‐L. & Bataille, R. ( 2003 ) CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood, 102, 1070 – 1071.en_US
dc.identifier.citedreferenceRosenblatt, J., Vasir, B., Uhl, L., Blotta, S., MacNamara, C., Somaiya, P., Wu, Z., Joyce, R., Levine, J.D., Dombagoda, D., Yuan, Y.E., Francoeur, K., Fitzgerald, D., Richardson, P., Weller, E., Anderson, K., Kufe, D., Munshi, N. & Avigan, D. ( 2011 ) Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood, 117, 393 – 402.en_US
dc.identifier.citedreferenceRossi, J.‐F., Manges, R.F., Sutherland, H.J., Jagannath, S., Voorhees, P., Sonneveld, P., Delforge, M., Pegourie, B., Alegre, A., de la Rubia, J., La Police, D., Bandekar, R., Xie, H. & Orlowski, R.Z. ( 2008 ) Preliminary Results of CNTO 328, An Anti‐Interleukin‐6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts), 112, Abstract 867.en_US
dc.identifier.citedreferenceRothenberg, M.L., Carbone, D.P. & Johnson, D.H. ( 2003 ) Improving the evaluation of new cancer treatments: challenges and opportunities. Nature Reviews Cancer, 3, 303 – 309.en_US
dc.identifier.citedreferenceSalles, G., Seymour, J.F., Offner, F., Lopez‐Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J.V., Brice, P., Caballero, D., Haioun, C., Pedersen, L.M., Delmer, A., Simpson, D., Leppa, S., Soubeyran, P., Hagenbeek, A., Casasnovas, O., Intragumtornchai, T., Ferme, C., da Silva, M.G., Sebban, C., Lister, A., Estell, J.A., Milone, G., Sonet, A., Mendila, M., Coiffier, B. & Tilly, H. ( 2011 ) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet, 377, 42 – 51.en_US
dc.identifier.citedreferenceSan Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.V., Anderson, K.C., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H. & Richardson, P.G. ( 2008 ) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359, 906 – 917.en_US
dc.identifier.citedreferenceSapra, P., Stein, R., Pickett, J., Qu, Z., Govindan, S.V., Cardillo, T.M., Hansen, H.J., Horak, I.D., Griffiths, G.L. & Goldenberg, D.M. ( 2005 ) Anti‐CD74 antibody‐doxorubicin conjugate, IMMU‐110, in a human multiple myeloma xenograft and in monkeys. Clinical Cancer Research, 11, 5257 – 5264.en_US
dc.identifier.citedreferenceShah, J.J., Zonder, J.A., Cohen, A., Weber, D., Thomas, S., Wang, M., Kaufman, J.L., Burt, S.M., Walker, D., Freeman, B., Rush, S.A., Ptaszynski, A., Orlowski, R.Z. & Lonial, S. ( 2010 ) A phase I/II trial of the KSP inhibitor ARRY‐520 in relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts), 116, Abstract 1959.en_US
dc.identifier.citedreferenceStevenson, G.T. ( 2006 ) CD38 as a therapeutic target. Molecular Medicine, 12, 345 – 346.en_US
dc.identifier.citedreferenceTai, Y.T., Podar, K., Gupta, D., Lin, B., Young, G., Akiyama, M. & Anderson, K.C. ( 2002 ) CD40 activation induces p53‐dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood, 99, 1419 – 1427.en_US
dc.identifier.citedreferenceTai, Y.T., Podar, K., Mitsiades, N., Lin, B., Mitsiades, C., Gupta, D., Akiyama, M., Catley, L., Hideshima, T., Munshi, N.C., Treon, S.P. & Anderson, K.C. ( 2003 ) CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3‐kinase/AKT/NF‐kappa B signaling. Blood, 101, 2762 – 2769.en_US
dc.identifier.citedreferenceTai, Y.T., Catley, L.P., Mitsiades, C.S., Burger, R., Podar, K., Shringpaure, R., Hideshima, T., Chauhan, D., Hamasaki, M., Ishitsuka, K., Richardson, P., Treon, S.P., Munshi, N.C. & Anderson, K.C. ( 2004 ) Mechanisms by which SGN‐40, a humanized anti‐CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Research, 64, 2846 – 2852.en_US
dc.identifier.citedreferenceTai, Y.T., Li, X.F., Catley, L., Coffey, R., Breitkreutz, I., Bae, J., Song, W., Podar, K., Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P., Treon, S.P., Grewal, I.S., Munshi, N.C. & Anderson, K.C. ( 2005a ) Immunomodulatory drug lenalidomide (CC‐5013, IMiD3) augments anti‐CD40 SGN‐40–induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Research, 65, 11712 – 11720.en_US
dc.identifier.citedreferenceTai, Y.T., Li, X., Tong, X., Santos, D., Otsuki, T., Catley, L., Tournilhac, O., Podar, K., Hideshima, T., Schlossman, R., Richardson, P., Munshi, N.C., Luqman, M. & Anderson, K.C. ( 2005b ) Human anti‐CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Research, 65, 5898 – 5906.en_US
dc.identifier.citedreferenceTai, Y.T., Dillon, M., Song, W., Leiba, M., Li, X.F., Burger, P., Lee, A.I., Podar, K., Hideshima, T., Rice, A.G., van Abbema, A., Jesaitis, L., Caras, I., Law, D., Weller, E., Xie, W., Richardson, P., Munshi, N.C., Mathiot, C., Avet‐Loiseau, H., Afar, D.E. & Anderson, K.C. ( 2008 ) Anti‐CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody‐dependent cellular cytotoxicity in the bone marrow milieu. Blood, 112, 1329 – 1337.en_US
dc.identifier.citedreferenceTassone, P., Gozzini, A., Goldmacher, V., Shammas, M.A., Whiteman, K.R., Carrasco, D.R., Li, C., Allam, C.K., Venuta, S., Anderson, K.C. & Munshi, N.C. ( 2004a ) In vitro and in vivo activity of the maytansinoid immunoconjugate huN901‐N2’‐deacetyl‐N2’‐(3‐mercapto‐1‐oxopropyl)‐maytansine against CD56+ multiple myeloma cells. Cancer Research, 64, 4629 – 4636.en_US
dc.identifier.citedreferenceTassone, P., Goldmacher, V.S., Neri, P., Gozzini, A., Shammas, M.A., Whiteman, K.R., Hylander‐Gans, L.L., Carrasco, D.R., Hideshima, T., Shringarpure, R., Shi, J., Allam, C.K., Wijdenes, J., Venuta, S., Munshi, N.C. & Anderson, K.C. ( 2004b ) Cytotoxic activity of the maytansinoid immunoconjugate B‐B4‐DM1 against CD138+ multiple myeloma cells. Blood, 104, 3688 – 3696.en_US
dc.identifier.citedreferenceTrikha, M., Corringham, R., Klein, B. & Rossi, J.F. ( 2003 ) Targeted anti‐interleukin‐6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clinical Cancer Research, 9, 4653 – 4665.en_US
dc.identifier.citedreferenceVeikkola, T., Karkkainen, M., Claesson‐Welsh, L. & Alitalo, K. ( 2000 ) Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Research, 60, 203 – 212.en_US
dc.identifier.citedreferenceVij, R., Horvath, N., Spencer, A., Taylor, K., Vadhan‐Raj, S., Vescio, R., Smith, J., Qian, Y., Yeh, H. & Jun, S. ( 2009 ) An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma. American Journal of Hematology, 84, 650 – 656.en_US
dc.identifier.citedreferenceVoorhees, P.M., Chen, Q., Small, G.W., Kuhn, D.J., Hunsucker, S.A., Nemeth, J.A. & Orlowski, R.Z. ( 2009 ) Targeted inhibition of interleukin‐6 with CNTO 328 sensitizes pre‐clinical models of multiple myeloma to dexamethasone‐mediated cell death. British Journal of Haematology, 145, 481 – 490.en_US
dc.identifier.citedreferenceWeber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., Borrello, I., Rajkumar, S.V., Chanan‐Khan, A.A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J.B. & Knight, R.D. ( 2007 ) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine, 357, 2133 – 2142.en_US
dc.identifier.citedreferenceWeiner, L.M., Surana, R. & Wang, S. ( 2010 ) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology, 10, 317 – 327.en_US
dc.identifier.citedreferenceYoshio‐Hoshino, N., Adachi, Y., Aoki, C., Pereboev, A., Curiel, D.T. & Nishimoto, N. ( 2007 ) Establishment of a new interleukin‐6 (IL‐6) receptor inhibitor applicable to the gene therapy for IL‐6–dependent tumor. Cancer Research, 67, 871 – 875.en_US
dc.identifier.citedreferenceZonder, J.A., Singhal, S., Bensinger, W., Mohrbacher, A., Hussein, M.A., Munshi, N.C., Caras, I., Singhal, A. & van Rhee, F. ( 2008 ) Phase I study of elotuzumab (HuLuc63) in relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts), 112, Abstract 2773.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2141.2011.08790.x.pdf
Size:
191.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.